By Maggie Fick <\/p>\n
LONDON, July 21 (Reuters) – Novo Nordisk said on Tuesday it was suing rival Eli Lilly in U.S. \u200cfederal court, accusing the U.S. drugmaker of false advertising in \u200cclaiming its weight-loss medicines outperform Novo’s drugs. <\/p>\n
The Danish company said it filed the lawsuit \u200bin U.S. District Court in New Jersey, alleging Lilly violated federal and state false advertising and unfair competition laws, including the Lanham Act, through nationwide advertising campaigns for obesity drug Zepbound and diabetes treatment \u200cMounjaro. <\/p>\n
Novo alleges Lilly compared \u2060the highest approved doses of its medicines with lower doses of Novo’s Wegovy and Ozempic while omitting newer, \u2060higher-dose versions that Novo says deliver greater weight loss. <\/p>\n
Novo said it is seeking a court order requiring Lilly to withdraw the advertisements and \u200brun a \u200bcorrective advertising campaign. It added \u200bthat it plans to seek \u200ca preliminary injunction if Lilly does not voluntarily remove the ads. <\/p>\n
Novo said it sent Lilly a cease-and-desist letter in April after the U.S. approved a 7.2-milligram dose of Wegovy. Lilly did not respond to the letter, Novo’s general counsel John Kuckelman told Reuters, adding that \u200cthe company instead inserted what he \u200bdescribed as an inadequate disclaimer into the \u200badvertisements. <\/p>\n
Kuckelman said Lilly’s advertisements \u200bcompare weight-loss results of about 50 pounds for Zepbound \u200cwith about 33 pounds for \u200bWegovy, even though \u200bno head-to-head trial has compared the highest approved doses of the medicines. He said separate late-stage trials of the highest doses \u200bshowed average weight \u200closs of about 48 pounds for Zepbound and 47 pounds \u200bfor Wegovy. <\/p>\n
(Reporting by Maggie Fick and Michael Erman; editing \u200bby Caroline Humer and Nia Williams) <\/p>\n","protected":false},"excerpt":{"rendered":"By Maggie Fick LONDON, July 21 (Reuters) – Novo Nordisk said on Tuesday it was suing rival Eli…\n","protected":false},"author":2,"featured_media":133336,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[276,64655,19843,272,280],"class_list":["post-133335","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-eli-lilly","tag-false-advertising","tag-federal-court","tag-novo-nordisk","tag-weight-loss"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116963448194562161","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/133335","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=133335"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/133335\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/133336"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=133335"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=133335"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=133335"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}